236 related articles for article (PubMed ID: 24697342)
21. Application of new measures of nonlinearity to parameter estimation and simulations in individual pharmacokinetic analyses.
Khinkis L; Crotzer M
J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):43-52. PubMed ID: 30607795
[TBL] [Abstract][Full Text] [Related]
22. Optimal design of mixed-effects PK/PD models based on differential equations.
Wang Y; Eskridge KM; Nadarajah S
J Biopharm Stat; 2012; 22(1):180-205. PubMed ID: 22204534
[TBL] [Abstract][Full Text] [Related]
23. [Comparison study of model evaluation methods: normalized prediction distribution errors vs. visual predictive check].
Ren YP; Deng CH; Wang XP; Zhou TY; Lu W
Yao Xue Xue Bao; 2011 Sep; 46(9):1123-31. PubMed ID: 22121786
[TBL] [Abstract][Full Text] [Related]
24. Role of modeling and simulation in pediatric investigation plans.
Manolis E; Osman TE; Herold R; Koenig F; Tomasi P; Vamvakas S; Saint Raymond A
Paediatr Anaesth; 2011 Mar; 21(3):214-21. PubMed ID: 21244569
[TBL] [Abstract][Full Text] [Related]
25. A comparison of nonlinear mixed-model analyses for a pediatric pharmacokinetic study.
Hartford A; Migoya E; Maganti L; Porras A; Zhang J
J Biopharm Stat; 2005; 15(3):465-78. PubMed ID: 15920891
[TBL] [Abstract][Full Text] [Related]
26. Outlier robust nonlinear mixed model estimation.
Williams JD; Birch JB; Abdel-Salam AS
Stat Med; 2015 Apr; 34(8):1304-16. PubMed ID: 25581342
[TBL] [Abstract][Full Text] [Related]
27. Drug dosage individualization based on a random-effects linear model.
Diaz FJ; Cogollo MR; Spina E; Santoro V; Rendon DM; de Leon J
J Biopharm Stat; 2012; 22(3):463-84. PubMed ID: 22416835
[TBL] [Abstract][Full Text] [Related]
28. Study design and simulation approach.
Läer S; Meibohm B
Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
[TBL] [Abstract][Full Text] [Related]
29. Assessing departure from dose linearity under a repeated measures incomplete block design.
Cheng B; Chow SC
Pharm Stat; 2011; 10(4):357-62. PubMed ID: 21104786
[TBL] [Abstract][Full Text] [Related]
30. Comparison of two design optimality criteria applied to a nonlinear model.
Bogacka B; Wright F
J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
[TBL] [Abstract][Full Text] [Related]
31. A mechanistic approach to understanding oral drug absorption in pediatrics: an overview of fundamentals.
Debotton N; Dahan A
Drug Discov Today; 2014 Sep; 19(9):1322-36. PubMed ID: 24846709
[TBL] [Abstract][Full Text] [Related]
32. The role of pharmacokinetic and pharmacokinetic/pharmacodynamic modeling in drug discovery and development.
Yu XQ; Wilson AG
Future Med Chem; 2010 Jun; 2(6):923-8. PubMed ID: 21426110
[No Abstract] [Full Text] [Related]
33. A point estimator for the time course of drug release.
Koehne-Voss S; Pigeot I
Biom J; 2009 Feb; 51(1):146-58. PubMed ID: 19219906
[TBL] [Abstract][Full Text] [Related]
34. Some general estimation methods for nonlinear mixed-effects models.
Davidian M; Giltinan DM
J Biopharm Stat; 1993 Mar; 3(1):23-55. PubMed ID: 8485535
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
[TBL] [Abstract][Full Text] [Related]
36. Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.
Ogungbenro K; Graham G; Gueorguieva I; Aarons L
J Biopharm Stat; 2008; 18(2):342-58. PubMed ID: 18327725
[TBL] [Abstract][Full Text] [Related]
37. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
38. Modelling and simulation in the pharmaceutical industry--some reflections.
Burman CF; Wiklund SJ
Pharm Stat; 2011; 10(6):508-16. PubMed ID: 22162317
[TBL] [Abstract][Full Text] [Related]
39. Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugs.
Nguyen TT; Bénech H; Delaforge M; Lenuzza N
Pharm Stat; 2016; 15(2):165-77. PubMed ID: 26689604
[TBL] [Abstract][Full Text] [Related]
40. The concordance correlation coefficient for repeated measures estimated by variance components.
Carrasco JL; King TS; Chinchilli VM
J Biopharm Stat; 2009; 19(1):90-105. PubMed ID: 19127469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
